PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Omar Mamlouk

The University of Texas MD Anderson Cancer Center

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 7, 2026 · JOURNAL ARTICLE

Immune checkpoint inhibitor usage in a sequential kidney transplant stage IV squamous cell carcinoma patient

Journal of Onco-nephrology

Single case report with no control group, describing tolerance of anti-PD-1 therapy in an unusual patient population; raises a question about feasibility rather than establishing efficacy or safety.

PreliminaryNeel Sampangirama Nonmelanoma Skin Cancer Studies Omar Mamlouk

Reported

Reported kidney transplant reject…as high as 40%

Patient transplant history durati…over 35 years

Number of sequential kidney trans…2

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support